Oddo BHF analyst Stephan Wulf upgraded Bayer (BAYRY) to Outperform from Neutral with a price target of EUR 55, up from EUR 39.80. The firm sees catalysts for the shares as the company’s litigation risks ease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer announces Kerendia meets primary endpoint in FIND-CKD study
- Bayer upgraded to Buy from Neutral at UBS
- Bayer price target lowered to EUR 53 from EUR 55 at Morgan Stanley
- Bayer Targets Earlier Prostate Cancer Use for Darolutamide With New China Phase 2 Trial
- Bayer Earnings Call: Solid Execution, Heavy Legal Overhang